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MD-1 is a member of the MD-2-related lipid-recogni-
tion (ML) family, and associates with RP105, a cell-
surface protein that resembles Toll-like receptor 4
(TLR4). The RP105,MD-1 complex has been pro-
posed to play a role in fine-tuning the innate immune
response to endotoxin such as bacterial lipopolysac-
charide (LPS) via TLR4,MD-2, but controversy sur-
rounds its mechanism. We have used atomically
detailed simulations to reveal the structural basis
for ligand binding and consequent functional dy-
namics of MD-1 and the RP105 complex. We ratio-
nalize reports of endogenous phospholipid binding,
by showing that they prevent collapse of the
malleable MD-1 fold, before refining crystallographic
models and uncovering likely binding modes for LPS
analogs. Subsequent binding affinity calculations
reveal that endotoxin specificity arises from the
entropic cost of expanding the MD-1 cavity to
accommodate bulky lipid tails, and support the role
of MD-1 as a ‘‘sink’’ that sequesters endotoxin from
TLR4 and stabilizes RP105/TLR4 interactions.
INTRODUCTION
MD-1 (myeloid differentiation protein 1) belongs to the MD-2-
related lipid-recognition (ML) family, comprising single-domain,
b-rich proteins (Figure 1) found in both animals and plants.
Despite their relatively low sequence identity and diverse physi-
ological functions, including roles in signaling, metabolism, and
defense, an emerging feature is the apparent shared ability to
interact with lipids (Inohara and Nun˜ez, 2002), and a correspond-
ing association with lipid-related disease states (Wymann and
Schneiter, 2008). MD-1 associates with RP105 (radioprotective
150 kDa), a type I transmembrane protein whose solenoidal ec-
todomain is composed of multiple leucine-rich repeats (LRRs)
(Figures 1A and S1A). MD-1 and RP105 share architecture and
cell-surface colocalization similar to that of the well-character-
ized MD-2/TLR4 (Toll-like receptor 4) system, which is key to
mounting an innate immunological response against invading200 Structure 24, 200–211, January 5, 2016 ª2016 Elsevier Ltd All rigpathogens (Gay and Gangloff, 2007; Park et al., 2009). This sug-
gests a role in sensing endotoxin or related microbial products,
since MD-2/TLR4 recognize bacterial lipopolysaccharide (LPS),
a large, complex glycolipid found in the outer membranes of
Gram-negative bacteria. Consistent with this, it has been re-
ported that RP105 may regulate LPS responses in a cell-depen-
dent manner, apparently fine-tuning TLR4 pathways, and also
regulating TLR2-inducedmacrophage responses toMycobacte-
rium tuberculosis lipoproteins (Blumenthal et al., 2009). Biologi-
cally this may be important in preventing overamplification of
the TLR4 response, which can lead to endotoxic shock, a prin-
cipal cause of death in intensive care units (Martin et al., 2003;
O’Neill et al., 2009).
MD-1 shares 20% identity with MD-2, and both protein
structures resemble a b cup with an almost exclusively hydro-
phobic lining, composed of a three-stranded and six-stranded
antiparallel b sheet (bC, bD, bG; and bA, bB, bI, bH, bE, and
bF; respectively) plus eight intervening loops (Figure 1B). Unlike
TLR4, RP105 does not contain the C-terminal Toll/IL-1 (TIR)
intracellular signaling domains necessary to transduce extracel-
lular signals into the cytoplasm (Gay et al., 2014). In addition, the
‘‘m-shaped’’ head-to-head organization of the RP105/MD-1
complex (Ohto et al., 2011; Yoon et al., 2011) juxtaposes the
RP105 N termini (Figures 1A and S1B), in contrast with the tail-
to-tail assemblies that facilitate interaction of the C-terminal
cytoplasmic TIR domains in TLR complexes. RP105 may fine-
tune endotoxin-induced activities through a direct interaction
with TLR complexes (Divanovic et al., 2005, 2007), possibly as
a result of the RP105 C-terminal region and MD-1 replacing
the equivalent homodimerization interface of the [TLR4,MD-2]2
receptor complex (Ohto et al., 2011; Yoon et al., 2011)
(Figure S1C).
In LPS molecules, the hydrophobic lipid anchor component
termed ‘‘lipid A’’ (LPA) contains a phosphorylated, b-(1,6)-linked
diglucosamine headgroup connected to multiple acyl tails (Alex-
ander and Zahringer, 2002) (Figure 2A), and is responsible for
most of the activity of LPS against TLR4. Hexa-acylated LPA
from Escherichia coli is a TLR4 agonist, and is endotoxic to hu-
man macrophage and mouse cells depending upon its structure
(Muroi et al., 2002; Bryant et al., 2010; Needham and Trent,
2013). The tetra-acylated precursor lipid IVa (LPIVa) (Kusumoto
et al., 2003) (Figure 2A) acts as an antagonist in human cells
but as an agonist in mouse cells (Golenbock et al., 1991; Means
et al., 2000). The immunomodulatory properties of different lipidhts reserved
Figure 1. Structure of RP105 Complex and MD-1
(A) Dimeric structure of the bovine 2:2 RP105,MD-1 complex, formed from
two copies of the primary 1:1 complex associated symmetrically through the
secondary dimerization interface. Chains in one of the 1:1 complexes are
labeled with an asterisk. The two RP105 chains are shown in green and blue
cartoons with the N and C termini labeled, and the two bound MD-1 chains are
shown in red and yellow. Glycans are shown in CPK stick representation. One
each of the primary (MD-1*/RP105*) and secondary (MD-1*/RP105) dimer-
ization interfaces is indicated. LRR numbers in RP105 are labeled.
(B) Structure of bovine MD-1, represented in cartoon format. Phe128 in the GH
loop and key interaction residues are shown in CPK wireframe representation
and labeled.
See also Figure S1.
Figure 2. Ligand Binding to MD-1
(A) Chemical structures of ligands employed, including (from left to right): hexa-
acylated lipid A from E. coli; tetra-acylated precursor lipid IVa; and DMPC
phospholipid, used here as amodel for unidentified, endogenous phospholipid
in the crystal structure of bovine MD-1 bound to RP105 (PDB: 3RG1).
(B–E) The MD-1 protein is shown bound to the initial ligand-bound state (red),
with the final 100-ns ligand conformations overlaid in shades of blue. The
final, overlaid conformations for three simulation replicas are shown for:
(B) iMD-1DMPC; (C) iMD-1LPIVa_cMD-1; (D) iMD-1LPIVa_hMD-2; and (E) iMD-1LPA.
(F) The initial (red) LPA conformation in the RP105 complex is compared
with the final positions within each MD-1 monomer (blue, green) of the
bRP105,MD-1LPA simulation.
In all snapshots, MD-1 is rendered in transparent cartoon format, with bound
ligand in wireframe format, while the initial conformation of F128 is shown in
gray wireframe format and labeled. In (B), the two edges of MD-1 and amino
(NT) and carboxy (CT) termini are indicated. In (C–F), the location of the two
phosphates are labeled. See also Figure S2.A analogs makes them of great biomedical interest (O’Neill et al.,
2009), but their low solubility (Galloway and Raetz, 1990;
Gutsmann et al., 2007) and complex phase behavior (Branden-
burg and Seydel, 2009; Gutsmann et al., 2007) complicates
structural and biophysical studies. A range of data is consistent
with the role of MD-1 as a lipid-binding protein, but the functional
significance, binding mode, and specificity remain controversial.
Observations of continuous electron densities attributable to
diacylated phosphatidylcholine (PC) and/or phosphatidyletha-
nolamine (PE) protruding from the cavity of isolated mouse
MD-1 (Harada et al., 2010) and phosphatidylglycerol in isolated
chicken MD-1 (Yoon et al., 2010) suggest a preference for inter-
action with endogenous lipids, drawing parallels with the MHC-
like CD1 receptors (Garzon et al., 2013). This was borne out in
the 2:2 [RP105,MD-1]2 complexes, revealing unidentified diacy-
lated ligands (Yoon et al., 2011) in bovine MD-1 or a mixture of
PC, PE, phosphatidylinositol, and phosphatidylserine in the
mouse and human complexes (Ohto et al., 2011). The lipid het-
erogeneity, binding mode, and weak associated densities are
indicative of a broad ligand capacity (Harada et al., 2010; Ohto
et al., 2011; Yoon et al., 2010, 2011). However, gel electropho-
resis and filtration analyses indicated that LPS specifically binds
to chicken and mouse MD-1 in a dose-dependent manner (Yoon
et al., 2010). A crystal structure of MD-1 bound to LPS has yet to
be obtained, but chicken MD-1 was co-crystallized with LPIVaStructure 24, 20(Yoon et al., 2010). It has been proposed that MD-1 may
sequester LPS from TLR4 components such as LPS-binding
protein, CD14, or MD-2, to modulate host sensitivity (Yoon
et al., 2011), and also that soluble MD-1 may facilitate opsoniza-
tion of Gram-negative bacteria (Yoon et al., 2010).
Structural differences between MD-1 and MD-2 may lead to
reduced affinity of MD-1 binding for LPS, providing a possible
explanation for previous reports that failed to detect a direct
interaction (Harada et al., 2010; Tsuneyoshi et al., 2005).
Compared with available MD-1 structures, significant conforma-
tional changes would be required to accommodate LPA within
the shallower MD-1 cavity, while there are fewer charged
patches available compared with MD-2 for interaction with the
polar LPA headgroup (Harada et al., 2010; Tsuneyoshi et al.,
2005; Yoon et al., 2010) (Figure S2). On the other hand, substan-
tial variations between MD-1 structures in the conformation of0–211, January 5, 2016 ª2016 Elsevier Ltd All rights reserved 201
Table 1. Summary of Unbiased Simulation Systems
System Name System Contents No. of Simulations and Length (ns)
iMD-1DMPC isolated bovine MD-1a + DMPC 3 3 100
iMD-1LPIVa_cMD-1 isolated bovine MD-1a + LPIVa (ligand position based on chicken MD-1 X-ray) 3 3 100
iMD-1LPIVa_hMD-2 isolated bovine MD-1a + LPIVa (ligand position based on human MD-2 X-ray) 3 3 100
iMD-1LPA isolated, expanded bovine MD-1b + LPA 3 3 100
iMD-1apo isolated ligand-free bovine MD-1a 6 3 100
iMD-1apo_exp isolated, expanded ligand-free bovine MD-1c 3 3 100
iMD-1apo (GROMOS/SPC) isolated ligand-free bovine MD-1a using GROMOS + SPC 1 3 100
iMD-1apo (OPLS/TIP3P) isolated ligand-free bovine MD-1a using OPLS + TIP3P 1 3 100
iMD-1apo (OPLS/TIP4P) isolated ligand-free bovine MD-1a using OPLS and TIP4P 1 3 100
iMD-1apo (CHARMM/TIP5P) isolated ligand-free bovine MD-1a using CHARMM and TIP5P 1 3 100
iMD-13myr isolated, expanded bovine MD-1c + three myristate molecules 1 3 100
iMD-14myr isolated, expanded bovine MD-1c + four myristate molecules 1 3 100
iMD-15myr isolated, expanded bovine MD-1c + five myristate molecules 1 3 100
iMD-16myr isolated, expanded bovine MD-1c + six myristate molecules 1 3 100
bRP105,MD-1LPA bovine (RP105,MD-1)2 complex + LPA
b 1 3 100
bRP105,MD-1apo bovine (RP105,MD-1)2 ligand-free complex
a 1 3 100
hRP105,MD-1LPA human (RP105,MD-1)2 complex + LPA
b 1 3 100
hRP105,MD-1apo human (RP105,MD-1)2 ligand-free complex
a 1 3 100
The starting structures used for iMD-1 simulations are as follows.
aPDB: 3RG1, MD-1 chain H.
bMore ’’open’’ protein from MD-1LPIVa_hMD-2 simulation, at time 41 ns.
cProtein from iMD-1LPA simulation, at time 100 ns. Unless stated otherwise, simulations were performed using CHARMM22/CMAP (Bjelkmar et al.,
2010; MacKerell et al., 1998) all-atom protein force field with TIP3P water model (Jorgensen et al., 1983).loops at the cavity entrance (including the EF and GH loops) and
b-sheet separation suggest that ligand-dependent changes in
cavity size may be possible (Harada et al., 2010; Ohto et al.,
2011; Yoon et al., 2010, 2011). Moreover, cavity adaptation
has been reported in experimental and computational studies
of other ML proteins (Ichikawa et al., 2005; Keber et al., 2005;
Paramo et al., 2013, 2014; Ichikawa et al., 2009).
The recognition of physiological ligands and potential fine-tun-
ing of immunological signal transduction by endotoxin remain ill
characterized. Given the similarity in sequence and structure of
MD-1 to MD-2, and currently available structural/biophysical
data, it seems likely that the two share functional characteristics.
In particular, we hypothesize: (1) that MD-1 should be malleable,
able to bind to a wide range of ligands which stabilize the pres-
ence of the enclosed cavity; and (2) that it may likewise bind to
bulky endotoxin with high affinity. In the latter case, this would
also then lead us to propose that (3) endotoxin may be bound
in the entire MD-1/RP105 complex, to occlude and, hence,
competitively inhibit the TLR4/MD-2 oligomerization interface.
To test these hypotheses, a series of atomically detailed molec-
ular simulations, amounting to 5 ms of sampling, have been
performed for the solvated, isolated bovine MD-1 (iMD-1) pro-
tein, and the entire 2:2 RP105/MD-1 complexes from human
(hRP105,MD-1) and bovine (bRP105,MD-1) species, in a range
of ligand-bound states (Table 1, Figure 2). We first demonstrate
that the cavity of MD-1 rapidly undergoes hydrophobic collapse
in its ligand-free (i.e. apo) state, but that this may be partially
averted in the presence of bound, diacylated phospholipid, sug-
gesting that its reported capacity for binding endogenous lipid
may serve tomaintain the presence of theMD-1 cavity. We refine202 Structure 24, 200–211, January 5, 2016 ª2016 Elsevier Ltd All rigthe only crystallographically available endotoxin-bound MD-1
structure, and show that an alternative ligand orientation that
more closely resembles LPIVa-bound MD-2 is thermodynami-
cally favorable, and better stabilizes the protein structure and
cavity. We then show that like MD-2 its cavity is highly malleable,
enabling it to adjust to the size and shape of endotoxin analogs.
While LPA exhibited a well-conserved, bound conformation
within MD-1, extensive biased sampling simulations reveal that
the b-cup fold presents a significant entropic cost that favors
LPIVa binding, thus explaining conflicting reports in the literature
of the interaction between endotoxin andMD-1. Finally, we show
that the architecture of the complete, heterotetrameric
RP105,MD-1 complex is relatively insensitive to the ligand-
bound state. However, we provide evidence for a well-
conserved endotoxin-binding site within the RP105 complex
resembling that of TLR4, suggesting that MD-1 may sequester
it from MD-2 to inhibit the LPS-induced TLR4 response.
RESULTS
Ligand-Free MD-1 Exhibits Cavity Collapse
Considering the apparent conformational heterogeneity of MD-1
and variable size of its associated cavity between different X-ray
structures, we first sought to characterize the underlying
dynamics of the protein via a number of 100-ns simulations
when free of ligand. Irrespective of the equilibration approach
or starting structure (Table 1), hydrophobic collapse of the largely
non-polar internal cavity was observed in the absence of endog-
enous ligand (Figures 3A–3D). This was reflected in the rapid
reduction in cavity volume, from 1.1 to 1.2 nm3 as observedhts reserved
Figure 3. Hydrophobic Collapse of the MD-1apo Cavity
Loss of cavity volume over 100 ns is shown for (A) all three replicas of iMD-1apo,
and (B) iMD-1apo_exp. In both cases, rapid initial hydrophobic collapse is inset.
Equivalent snapshots following ligand removal at 0 ns (left) and 100 ns (right)
are shown for (C) iMD-1apo and (D) iMD-1apo_exp. In both cases, non-polar side
chains inside the cavity are shown as spacefill, with water molecules shown in
stick format. Overlays of the final collapsed structures of the MD-1 protein
upon ligand removal are shown in cartoon representation, generated using (E)
different protein force fields including iMD-1apo (black), iMD-1apo(AMBER/TIP3P)
(red), iMD-1apo(GROMOS/SPC) (blue), and iMD-1apo(OPLS/TIP3P) (green); and (F)
different water models including iMD-1apo (black), iMD-1apo(CHARMM/TIP5P)
(gray), iMD-1apo(OPLS/TIP3P) (green), and iMD-1apo(OPLS/TIP4P) (teal).
See also Figure S3.
Figure 4. Conformational Plasticity of iMD-1
(A) CaRMSDwith respect to the bovine crystal structure (PDB: 3RG1, chain H),
for a range of ligand-bound states. RMSDs were calculated after fitting to the
same group, thereby reporting on internal structural drift.
(B) Final binding cavity volumes in iMD-1 in a range of ligand-bound states.
In (A) and (B), data are averaged over the final 20 ns of simulation, and over
three replicas, with error bars indicating the corresponding standard de-
viations. See also Figure S4.in the X-ray structure of the bRP105,MD-1 complex, presumed
to be bound to unidentified diacylated phospholipids (Yoon
et al., 2011), to just 0.1 nm3 within the first few nanoseconds
of each simulation (Figure 3A). This was followed by fluctuations
around this size over subsequent tens of nanoseconds, without
any further significant changes. The rapid hydrophobic collapse
was facilitated by closure of the cavity mouth, leading to loss of
most accessible pathways from cavity to solvent, and was
accompanied by rapid desolvation of the cavity, leaving only
four to five water molecules weakly bound on the surface of
the cavity (Figure S3A). Limited hydrogen bonds (H bonds)Structure 24, 20were observed between polar residues on the edges of the cavity
during this process (Figure S3C), with a single transient H bond
between residues Y96 and N124. Thus, the driving force for sta-
bilization of the closed state came primarily from hydrophobic in-
teractions and entropically favorable expulsion of water. Similar
observations could be made for additional 100-ns simulations of
the RP105-bound state, with a mean final cavity volume for the
pair of MD-1 chains of 0.1 nm3 for both bRP105,MD-1apo
and hRP105,MD-1apo (Figure S4C).
To ensure reproducibility, five additional iMD-1apo simulation
trajectories were also generated using various all-atom and
united-atom protein force fields and water models (Table 1). In
all cases a similar overall behavior was observed, with a rapid
initial cavity collapse. The structural drift for the backbone atoms
of the entire protein and b-cup fold was similar across iMD-1 sys-
tems, exhibiting a mean root-mean-square deviation (RMSD) of
0.25–0.3 nm and 0.15–0.2 nm, respectively, in comparison
with the X-ray structure (PDB: 3RG1) of the ligand-bound bovine
complex (Figures 4A and S4A). In the receptor-bound state, the
MD-1 protein exhibited significantly less structural drift due to
the stabilizing effect of surrounding RP105 contacts, with
0.05–0.1 nm less RMSD in each case (Figure S4B). Irrespective
of force field or starting structure, a comparable collapsed pro-
tein fold was obtained (Figures 3E and 3F). The protein second-
ary structure wasmostly conserved in apo systems (Figure S4D),0–211, January 5, 2016 ª2016 Elsevier Ltd All rights reserved 203
Table 2. Mean Short Range van der Waals and Coulombic







iMD-1DMPC 303 ± 27 85 ± 49
iMD-1LPIVa_cMD-1 381 ± 32 128 ± 123
iMD-1LPIVa_hMD-2 459 ± 35 175 ± 154
iMD-1LPA 452 ± 22 61 ± 36with collapse of the cavity resulting primarily from spontaneous
shifts in the positions of the two opposing b sheets on either
side of the cavity entrance, along with flexibility of the intervening
loops, so that strands bF, bE, and bH on edge 2 and bD/bG on
edge 1 came together to close off the cavity (Figures 3E and
3F). However, partial shortening by one or two residues of
strands bA, bC, bF, and bG was observed, the latter due to the
destabilization of the intervening loop GH (Figures 3 and S4D).
Similar protein dynamics were also observed when comparing
the per-residue root-mean-square fluctuations (RMSFs) be-
tween iMD-1apo and iMD-1apo_exp systems, with the largest fluc-
tuations corresponding to parts of loops EF (residues 87–89), FG
(residues 100–110), and HI (residues 142–145) (Figure S4E). The
observed variability of loops and capacity for sheet separation/
closure are consistent with differences between variably sized
ligand-bound experimental structures of MD-1 (Harada et al.,
2010; Ohto et al., 2011; Yoon et al., 2010, 2011) and with exper-
imental and computational studies (Paramo et al., 2013, 2014) of
other ML family members. Moreover, the nanosecond time-
scales associated with loss of the MD-1 cavity are in agreement
with experimentally characterized protein hydrophobic collapse
(Sadqi et al., 2003).
Bound Endotoxin Stabilizes the Malleable MD-1 Cavity
Given the tendency for the MD-1 cavity to collapse when free of
ligand, we next sought to establish the possible stabilizing role of
endogenous and bacterial lipids. Thus, a series of triplicate
100-ns simulation trajectories were generated for iMD-1 in the
presence of ligands. Since the X-ray structure of bovine
RP105,MD-1 was co-purified with an unidentified, diacylated
phospholipid, an initial control system was built with a single di-
myristoylphosphatidylcholine (DMPC) molecule modeled within
the cavity binding site (iMD-1DMPC). Moreover, in light of the pro-
posed role of MD-1 in modulating the TLR4 response to endo-
toxin, the protein was also simulated in the presence of LPA
(iMD-1LPA), guided by the available crystal structure of LPS-
bound MD-2. Finally, given the reports of affinity of MD-1 for
LPIVa, a biosynthetic endotoxin precursor, two systems were
also set up with alternative lipid conformations based on crystal
structures of LPIVa-bound chicken MD-1 (iMD-1LPIVa_cMD-1) and
human MD-2 (iMD-1LPIVa_hMD-2).
Based on the iMD-1DMPC system, the presence of a simple hy-
drophobic ligand is sufficient to at least partially stabilize the
malleable MD-1 cavity compared with the apo state. While the
single DMPC molecule remained bound throughout, it exhibited
high mobility among simulation replicas. The tail conformations
aligned to varying degrees along the cavity axis (Figure 2B),
while the phosphatidylcholine headgroup shifted by as much204 Structure 24, 200–211, January 5, 2016 ª2016 Elsevier Ltd All rigas 1 nm compared with its initial position. This was reflected
by the disparity in the number of polar ligand-protein contacts
between simulation replicas. Extremely short-lived salt bridges
with the choline group were observed in some but not all replicas
(Figure S5G), with one or two additional H bonds formed be-
tween the glycerol backbone, phosphate groups, and various
residues at the cavity opening (Figures 1B, S5G, and S5H). Res-
idues Y96 on bF, and N124/N125 in loop GH contacted either an
acyl chain or a phosphate group, the latter also fleetingly inter-
acting with K105 occasionally (itself competing with nearby
E100). In the third replica, the ligand moved toward loop GH
and edge 2, the second acyl chain interacting with the backbone
of residues F128 and E129. These variable results and lack of po-
lar interactions are consistent with the average interaction en-
ergies between protein and ligand, with 80% contributed by
Lennard-Jones versus electrostatic energies (Table 2). The pro-
tein dynamics profiles (Figure S4E) and secondary structure pro-
pensities (Figure S4D) further highlight the variability between
replicas. Different RMSF peaks (>0.2 nm) were observed in alter-
native regions between replicas, while a slight shortening of
strands bF and bG was observed in two replicas compared
with loss of structure across strands bA, bE, bF, bG, and bH on
edge 2 in the third, similarly to the apo systems. The lack of spe-
cific binding mode is consistent with the adaptation of the cavity
(Figure 5B), reducing in size compared with the X-ray structure to
a final volume of 0.6 nm3 (Figure 4B), and the absence of sub-
stantial patches of charged or H-bonding donors around the
cavity mouth to facilitate long-lived headgroup interactions (Fig-
ure S5C). This indicates that additional hydrophobic molecules
from endogenous sources or crystallization media may
contribute to the unidentified density within the MD-1 cavity
(Yoon et al., 2011; Ohto et al., 2011).
The presence of LPIVa stabilized the MD-1 binding cavity
more significantly, and the lipid tails remained relatively close
to their initial orientation, with fluctuations in position limited to
the most exposed acyl tail at the cavity mouth (Figures 2C and
2D). The diglucosamine headgroups were better stabilized
than the phosphatidylcholine groups in the DMPC system, with
several long-lived polar contacts evident (Figure S5G). Neverthe-
less, iMD-1LPIVa_cMD-1 exhibited shifts compared with the crystal
structure, with only a rather unstable/transient salt bridge, and
fluctuating H bonds formed around the rim of the binding pocket
(Figures S5G and S5H). In the original reported X-ray structure of
chicken MD-1, the glycosidic linkage of the LPIVa headgroup
was built in a biologically unrepresentative a-(1,6) form, possibly
due to uncertainty in the crystallographic density (Yoon et al.,
2010). Comparison with human MD-2-bound (Ohto et al., 2007)
LPIVa reveals that its b-(1,6)-linked glucosamine backbone is
rotated by 180 and shifted toward edge 2 (Figures S5A and
S5B), and indeed, the iMD-1LPIVa_hMD-2 simulation replicas
generated based on this conformation exhibited a significantly
better conserved headgroup position (Figure 2C versus 2D),
anchored by longer-lasting polar interactions involving residues
on strands bF, bG, and loop GH (Figures S5G and S5H). The po-
lar residues that contacted lipid in the iMD-1LPIVa_cMD-1 system
included those also observed in the DMPC-bound state,
including Y96, N124, N125, and, partially, K105, interacting
with the P1 phosphate group and hydrophilic moieties associ-
ated with the nearby sugar ring and acyl chains. Key interactionshts reserved
Figure 5. Conformational Dynamics of the MD-1 Cavity
(A) Correlation between MD-1 cavity size and the total number of aliphatic
carbons within the tail of each bound ligand, based on all simulation states
reported here. R2 = 0.96 for all data points. Data are averaged over the final
20 ns of simulation, with error bars indicating the corresponding standard
deviations.
(B) Average MD-1 cavity surface over the last 20 ns of simulation, calculated
with trj_cavity (Paramo et al., 2014). Surfaces with a >90% probability are
shown as solid, and ones with >50% probability are shown as transparent.
Protein is rendered in cartoon representation.
See also Figure S5.in iMD-1LPIVa_hMD-2 also occurred along edge 1, with Y96, K105,
and N124 anchoring phosphate P2, along with associated sugar
ringmoieties and acyl chains. However, additional contacts were
now observed on loop GH between the backbone of residues
G127, E129, and two acyl chains. While the RMSF profiles for
both systemswere very similar (Figure S4E), several larger peaks
in fluctuation were observed for iMD-1LPIVa_cMD-1, including in
strand bF, loop FG, and loop GH. Consistently, more disruption
of the secondary structure was observed in this system,
including in strands bA, bD, bF, bG, and bH (Figure S4D). The
opposite effect was observed for iMD-1LPIVa_hMD-2, with broad-
ening of several b strands including bA, bB, and bG, compared
with the crystallographic state. This alternative LPIVa-bound
conformation also resulted in improved cavity stabilization; a
final volume of0.8 nm3 for iMD-1LPIVa_hMD-2 indicated no signif-
icant change in size relative to the equivalent experimental struc-
ture, compared with a loss of 0.1 nm3 for iMD-1LPIVa_cMD-1,
presumably as a result of weakened ligand anchoring within
the protein. The potential energies of lipid-protein interaction
further support these observations; thus, a 25% increase in total
interaction energy was observed for iMD-1LPIVa_hMD-2 compared
with iMD-1LPIVa_cMD-1, distributed approximately equally across
van der Waals and Coulombic terms (Table 2).
Finally, modeled LPA exhibited a well-conserved bound
conformation across simulation replicas. The LPA tails remainedStructure 24, 20within the cavity (Figure 2E), supported by long-lived H bonds
(Figure S5G) formed by residues along edge 1, again including
Y119, N124, and N125 (Figure S5H), although the phosphate
groups were largely exposed to solvent. The final volume of
the cavity reached 1.1 nm3 (Figure 4B), similar to that found
in the X-ray structure of the bRP105,MD-1 complex (Yoon
et al., 2011), with the now fully open cavity (Figure 5B) com-
fortably shielding the bulk of the hydrophobic molecule from sol-
vent. Similar conservation of the LPA-binding mode was
apparent for RP105-bound MD-1 (Figure 2F) in both the bovine
(bRP105,MD-1LPA) and human (hRP105,MD-1LPA) complexes,
while the bRP105,MD-1LPA cavity expanded its capacity to a
maximum of 1.4 nm3 to adapt to the presence of endotoxin
(Figure S4C). The protein dynamics appeared somewhat damp-
ened compared with other systems (Figure S4E), suggesting that
the large hydrophobic lipid tail component acted as a tightly
bound ‘‘plug’’ that restricted fluctuations of the b-cup fold, and
consistently the secondary structure was well conserved
compared with the crystallographic state (Figure S4D). While
the electrostatic interaction energies between protein and ligand
were limited due to the bulky ligand being pushed out of the cav-
ity, interactions due to the acyl tails were maximized, resulting in
the magnitude of van der Waals interaction reaching a value
similar to that of iMD-1LPIVa_hMD-2 (Table 2).
Collectively, comparison across all systems reveals an excel-
lent correlation betweenMD-1 internal cavity size and total num-
ber of aliphatic carbons in the bound lipid tails, both in the
isolated state and in the receptor complex (Figure 5A). Thus,
its volume can spontaneously increase from <0.2 nm3 in the
absence of ligand to 0.6 and 0.8 nm3 in the presence of di-
versus tetra-acylated species, respectively, and as much as
1.1–1.4 nm3 when bound to hexa-acylated lipid A. A trend of
gradually increasing RMSD of the protein fold as lipid size and,
hence, cavity stabilization reduced was observed (Figure 4A), re-
flecting the tendency for the b hairpins and associated loops at
the cavity mouth to adapt to bound ligand. In the LPA-bound
form, as well as in the iMD-1LPIVa_hMD-2 system, the secondary
structure of MD-1 was extremely well maintained and the protein
structural drift was significantly reduced in comparison with the
ligand-free structures, with a backbone RMSD of0.15 nm (Fig-
ure 4A). This again suggests that various endotoxin analogs,
when optimally bound, appear to act as a ‘‘plug’’ to stabilize
the malleable MD-1 fold relative to available experimental
structures.
Receptor Complex Stability Is Not Dependent upon
Ligand Binding
While the internal cavity of RP105-complexed MD-1 was simi-
larly adaptable to the isolated form (Figure S4C), the stability of
the protein fold was apparently unresponsive to ligand.
Comparing the final, fitted Ca RMSDs, however (Figures 4A
and S4B), suggests that the presence of the receptor can stabi-
lize the structural drift of the b-cup fold and surrounding loops of
MD-1 relative to the X-ray structure by as much as 0.1–0.15 nm.
It is of interest to consider the ligand-dependent behavior of the
receptor complex as a whole, since models for competitive
inhibition of LPS-induced TLR4,MD-2 oligomerization (Ohto
et al., 2011; Yoon et al., 2011) would likely depend upon the sta-
bility of RP105,MD-1. While the TLR4 and RP105 complexes0–211, January 5, 2016 ª2016 Elsevier Ltd All rights reserved 205
Figure 6. Stability of the RP105,MD-1 Complex
(A) Mean surface area buried between MD-1 and RP105 at the primary (right
graph) and secondary dimerization (left graph) interfaces, calculated for the
two equivalent sites (filled or empty bars) within each receptor complex.
(B) Distance between pairs of equivalent LRRs on opposing RP105 chains,
shown for bovine (left graph) and human (right graph) complexes.
Data in all graphs are averages over the last 20 ns of simulation, with error bars
indicating the corresponding standard deviations. See also Figure S6.differ in their tail-to-tail versus head-to-head arrangements,
respectively, they are otherwise stabilized by a similar set of in-
teractions with their co-receptor partners. Thus, RP105 forms
a 1:1 ‘‘primary’’ interface with MD-1 (Figures 1 and S1). Similarly,
a ‘‘secondary’’ dimerization interface exists between pairs of
RP105,MD-1 dimers (RP105*/MD-1 and RP105/MD-1*) to com-
plete the heterotetrameric complex (Figures 1 and S1), although
these are formed by the N-terminal rather than C-terminal do-
mains due to the inverse arrangement.
During simulation, the primary interface was stable in both the
LPA-bound and free bovine RP105,MD-1 systems, its buried
surface area (bSA) increasing from10.5 nm2 in the X-ray struc-
ture to 11–12 nm2 (Figure 6A). For the unbound human com-
plex, significant asymmetry in bSA was observed at the primary
site in the absence of ligand, indicating a possible role for aspar-
agine-linked glycans (Figure S1A) in maintaining stability,
although co-expression of a mutant, non-glycosylated bovine
RP105 with MD-1 results in formation of relatively stable com-
plexes (Yoon et al., 2011). The two equivalent interaction inter-
faces became buried to a similar degree upon binding of LPA,
reaching 13 nm2 of bSA (Figure 6A). As described above, the
LPA molecule adopted a highly conserved conformation within
the receptor-bound MD-1 pockets (Figure 2F), as in the isolated
MD-1 system replicas (Figure 2E). Moreover, its headgroup was206 Structure 24, 200–211, January 5, 2016 ª2016 Elsevier Ltd All rigstabilized by a number of electrostatic interactions between
phosphate groups, acyl oxygens, and residues on LRRs 9–14
of the RP105 chains (Figure S6). Many of the longest-lived inter-
actions were counterion crosslinked rather than direct H bonds,
whichmay serve to provide flexibility in the ligand-bindingmode.
Similar contact residues shared between the bRP105,MD-1LPA
and hRP105,MD-1LPA complexes included Glu256, Asp259,
and Lys/Glu283 (Figure S6B). Long-lived LRR-phosphate inter-
actions crosslinked by cations observed in the RP105 simula-
tions resembled those in the human TLR4 crystal structure
(Park et al., 2009), and in previous simulations of TLR4 (Paramo
et al., 2013). In general, protein-lipid interactions shared counter-
parts in TLR4, suggesting that this does indeed represent a true
binding site for LPS and related analogs.
Importantly, the RP105 dimerization interface was extremely
stable across all systems (Figure 6A), helping to maintain the po-
sition of the two RP105 chains with respect to one another (Fig-
ure 6B). Thus, the values of 17 or 19 nm2 for bSA between
RP105* and MD-1 observed crystallographically at human and
bovine sites, respectively, were approximately maintained in
the absence of ligand, and further stabilized upon LPA binding.
The maintenance of the tetrameric receptor complex structure
was consistent with the limited structural drift exhibited by
RP105 and its individual components (Figure S6C) including
the N-terminal and central domains, which encompass the key
protein-protein oligomerization interfaces (Figure S1). The C-ter-
minal region demonstrated the greatest deviation, although its
RMSD was still limited to less than 0.2 nm with respect to the
experimental conformations across all systems (Figure S6C).
Likewise, the separations between successive LRRs remained
close to those of the equivalent X-ray crystal structures, with
small shifts toward the C termini likely a result of the lack of mem-
brane anchor within the ectodomain construct (Figure 6B).
Collectively, these observations demonstrate that while LPA
may be stably bound by RP105,MD-1, the overall architecture
of the receptor complex is relatively insensitive to the ligand-
bound state. This is consistent with the ability of the 2:2
RP105,MD-1 complex to reportedly interact with a range of
endogenous ligands (Harada et al., 2010; Ohto et al., 2011;
Yoon et al., 2010, 2011), and is in stark contrast to the exquisite,
species-dependent specificity of TLR4. Experimental (Kim et al.,
2007; Kobayashi et al., 2006; Ohto et al., 2007; Park et al., 2009;
Yu et al., 2012) and computational (Paramo et al., 2013) studies
suggest that agonist binding to TLR4,MD-2 is essential to main-
tain the signaling-competent heterotetramer, and that the orien-
tation of the conserved residue Phe126 in the GH loop of MD-2 is
critical in determining the ligand-dependent activity of the com-
plex, by allosterically modulating the dimerization interface crit-
ical for signaling (Paramo et al., 2013; Yu et al., 2012). We saw
no evidence that aromatic residues located the GH loop of
bovine (Phe128) or human (Phe131) MD-1 play any obvious
mechanistic function in receptor ‘‘signaling,’’ since no system-
atic correlation between the nature of bound ligand (or indeed
apo state) and loop conformational change (Figures 4 and S4)
was apparent during simulations of MD-1 in its isolated state
or when bound to receptor, and only limited contacts were
observed between this region and lipid (Figure S5H). Thus, the
endotoxin-dependent conformational switching mechanism
present in the TLR4,MD-2 system (Paramo et al., 2013; Yuhts reserved
Figure 7. Energetic Basis for Lipid Binding to MD-1
(A) Potential of mean force (PMF) curves for endotoxin binding to iMD-1, and associated protein cavity volume and buried surface area between protein and lipid,
calculated as a function of z. PMFLPA and PMFLPIVa represent binding of LPA and LPIVa to the unrestrained protein, respectively, while rPMFLPA represents the
binding of LPA to the position-restrained protein. The center of the protein is at z = 0 nm, and PMFs have been normalized so that the minimum lies at 0 kJ mol1.
PMF values for systems rPMFLPA, PMFLPA, and PMFLPIVa in 0.1 M solution are, respectively, 288 ± 4, 169 ± 2, and 188 ± 3 kJ mol1. Mean and SDs are shown for
the final 5 ns of the corresponding PMF windows.
(B) The pathway associated with the LPA binding PMFs to unrestrained iMD-1, shown at different positions along z. Protein is shown in cartoon format, with lipid
and key interacting residues in wireframe representation.
See also Figure S7.et al., 2012) does not appear to be relevant here. It is also worth
noting that in predicted structural models for inhibitory interac-
tion between TLR4,MD-2 and RP105,MD-1, loop GH may not
occlude the adjacent TLR4,MD-2 unit (Figure S1C) (Yoon
et al., 2011).
LPIVa Binding to MD-1 Is Entropically Favored over LPA
While LPA appears to be non-essential for stabilization of the 2:2
RP105,MD-1 complex, binding would nevertheless serve to
sequester it from TLR4, and may also favor interaction between
RP105,MD-1 and TLR4,MD-2 to competitively inhibit the latter.
Having shown that both LPIVa and LPA may stably occupy the
MD-1 cavity, we next sought to quantitatively establish their pref-
erence for binding. An accurate estimate of the potential of mean
force (PMF) and, hence, free energy (DG) associatedwith binding
for LPIVa (PMFLPIVa) and LPA (PMFLPA) was thus obtained by
performing umbrella sampling calculations. During these calcu-
lations, a series of molecular dynamics simulations (amounting
to >2 ms of sampling) were generated, whose configurations cor-
responded to the ligand being transferred reversibly from the
MD-1-binding site into solvent.
In Figure 7A, the PMFs for each ligand are shown as a function
of z, the cavity axis, with representative snapshots along this
pathway depicted in Figure 7B. LPIVa and LPA occupy similar lo-
cations along z at their bound equilibrium, at 1.4 and 1.7 nm,
respectively, the latter lying slightly further toward solvent as a
result of its bulkier acyl tail region. Both lipids demonstrate
some capacity to shift around this equilibrium position by a few
angstroms without disruption of key lipid-protein interactions,Structure 24, 20thus incurring no significant energetic penalty. The bound state
of both ligands is stabilized largely by hydrophobic interactions,
with four (LPIVa) or six (LPA) acyl tails apparently bound to ‘‘satu-
ration,’’ with comparable solvent-accessible surface areas of
25 nm2 buried by MD-1 (Figure 7A), similar to the values
observed for LPIVa- and LPA-complexed MD-2 (Paramo et al.,
2013). Hydrophilic interactions seem to be less important, with
only one or two H bonds or counterion crosslinked salt bridges
formed between polar amino acid side chains and lipid head-
group throughout each PMF (Figures 7B and S7B), consistent
with our observations from the unbiased simulations described
above (Figure S5) and with the lack of charged residues at the
cavity entrance of MD-1, in contrast with MD-2 (Figure S2).
A smooth rise in free energy is observed as each ligand is grad-
ually extracted, with a concomitant drop in bSA (Figure 7A),
before finally exiting the cavity around1.7 nm beyond the equi-
librium-bound state.
An abrupt plateau in free energy represents the moment that
each lipid becomes fully dissolved within the bulk solvent phase
(Figure 7A). The difference between each PMF at this point
and the bound state yields DG, and reveals that MD-1 exhibits
a greater affinity for LPIVa (188 ± 3 kJ mol1) than for LPA
(169 ± 2 kJ mol1). Additional PMFs calculated in the absence
of 0.1 M salt led to comparable profiles but an approximate
drop in DG of 15% (Figure S7A), due to the loss of transient
counterion-mediated headgroup interactions with Y119, N124,
and E129 (Figure S7), replaced by water-mediated H bonds,
further reiterating the dominance of hydrophobic contacts
throughout the (un)binding process. When analyzing the total0–211, January 5, 2016 ª2016 Elsevier Ltd All rights reserved 207
Table 3. Structural Properties of MD-1 Bound to Different
Numbers of Myristate Fatty Acid Molecules
No. of Bound
Myristate Molecules
Mean % of Acyl
Carbons Exposed
to Waterb
Ca RMSD with Respect to
X-ray Structure (nm)c
3 19.8 ± 39.8 0.22 ± 0.01
4 21.9 ± 41.3 0.21 ± 0.01
5 29.7 ± 45.7 0.24 ± 0.02
6a 40.0 ± 48.9 0.25 ± 0.02
aDuring this simulation, one fatty acid molecule spontaneously exited the
cavity.
bWater-exposed acyl carbon defined as being within%0.4 nm from any
water molecule.
cFor reference, the final LPS-bound simulation structure, which was used
to initiate myristate-bound simulations, had an RMSD of 0.28 nm with
respect to the X-ray structure.number of protein-ligand contacts per window (Figures S7E
and S7F), over an order of magnitude greater hydrophobic in-
teractions are observed along the bound state compared with
polar ones. Hydrophobic contacts are completely lost in the
3.0- to 3.5-nm range along z relative to the protein center of
mass.
The binding preference of MD-1 appears to arise from the
plasticity of the b-cup fold, and its inherent capacity that better
matches the size of LPIVa. During the initial 1 nm along the
pathway of ligand extraction, the LPA-bound cavity undergoes
hydrophobic collapse with a loss of0.5 nm3, whereas for LPIVa
the volume remains approximately constant over this range,
prior to subsequent collapse upon further extraction of each
ligand (Figure 7A). To confirm this hypothesis, we calculated
additional PMFs for LPA binding in the absence of cavity dy-
namics (rPMFLPA), by harmonically fixing the b-cup fold. In this
case DG was almost doubled, confirming that there is indeed a
large entropic cost for MD-1 to bind the large LPA acyl tails. In
further support of this, we estimate that in the fully LPA-bound
state of MD-1, its cavity is still at least 25% smaller than that
of MD-2 (Paramo et al., 2013). As a final test, we ran 100-ns sim-
ulations of MD-1 with varying numbers of bound myristic acid
molecules. These revealed that beyond four acyl chains, the li-
gands exhibited partial protrusion or even expulsion from the
binding cavity (Figure S7I; Table 3), supportive of the inherent
capacity of MD-1 to better match the size of smaller endotoxin
molecules such as LPIVa.
DISCUSSION
In this study, we have rationalized available structural and bio-
physical data to support the heterogeneity of MD-1 in its mode
of binding and specificity for ligand type (Harada et al., 2010;
Ohto et al., 2011; Yoon et al., 2010, 2011). MD-1 is highly
malleable, its cavity able to adjust to precisely match its volume
according to the bound lipid ligand. Such dynamic adaptability is
emerging as a common evolutionary theme across the ML pro-
tein superfamily (Paramo et al., 2013, 2014; Ichikawa et al.,
2005; Ichikawa et al., 2009; Keber et al., 2005). Concomitant
with these changes in cavity size, a capacity for the loops and
two b sheets to adopt different relative conformations was208 Structure 24, 200–211, January 5, 2016 ª2016 Elsevier Ltd All rigobserved, helping to explain analogous differences between
available MD-1 X-ray structures (Harada et al., 2010; Ohto
et al., 2011; Yoon et al., 2010, 2011). Rapid hydrophobic collapse
in the ligand-free state—highly reproducible and consistent with
experimentally measured timescales (Sadqi et al., 2003)—and its
preclusion by cavity-resident phospholipid (Ohto et al., 2011;
Yoon et al., 2011) is suggestive of the requirement for bound
endogenous ligand to support long-term cavity stability, in a
manner similar to that of other lipid-binding protein families (Gar-
zon et al., 2013).
The large endotoxin molecules, LPIVa and LPA, adopted sin-
gle, well-defined conformations across simulation replicas and
systems, acting as a ‘‘plug’’ to stabilize the flexible MD-1 fold,
relative to available experimental structures. Comparison of
protein-ligand complex dynamics in the presence of the crys-
tallographically guided LPIVa with an a-(1,6)-linked diglucos-
amine backbone (Yoon et al., 2010) and the naturally occurring
b-(1,6) form suggest that the latter, when rotated by 180 within
MD-1 to resemble the X-ray structure of LPIVa-bound MD-2,
represents the likely conformation in vivo. Thus, these simula-
tions help to inform and refine our knowledge of the holo-pro-
tein based on the single crystallographic study to date of MD-1
bound to endotoxin. Likewise, a model of LPA-bound MD-1
based on its crystallographic MD-2 counterpart was shown to
be stably bound within the cavity. From an energetic perspec-
tive, our calculations of complete binding PMFs indicate that
both LPIVa and LPA exhibit a strong affinity for the hydrophobic
MD-1 cavity, stabilized largely by hydrophobic interactions,
much like MD-2 (Paramo et al., 2013). The low solubility of
such ligands (Gutsmann et al., 2007; Santos et al., 2003;
Yu et al., 2006) prevents measurement of true equilibria be-
tween solvated and protein-bound forms, and hence compli-
cates experimental validation (Prohinar et al., 2007). However,
extrapolation from biophysical (Israelachvili, 2011; Seydel
et al., 2000) and computational models (Pieffet et al., 2014; Tie-
leman and Marrink, 2006) for simpler surfactant and lipid mole-
cules suggests that an increment of 3–4 kJ mol1 per CH2
group is required for transfer between water and aggregate
phases, consistent with our calculated binding free energies
for tetra-acylated LPIVa. Harada et al. (2010) previously pro-
posed that along with changes in the electrostatic surface,
the shallower cavity and narrower entrance of MD-1 in compar-
ison with MD-2 may hamper LPS binding, although Yoon et al.
(2010) reported dose-dependent association of LPS with
mouse MD-1. We have shown here that the expansion of the
MD-1 cavity necessary for accommodating the bulky lipid tail
component of hexa-acylated LPA represents a significant addi-
tional entropic cost that effectively lowers its affinity compared
with LPIVa. This helps to explain conflicting experimental re-
ports of a direct interaction between LPS and MD-1 (Harada
et al., 2010; Tsuneyoshi et al., 2005; Yoon et al., 2010), with
only an LPIVa-bound crystal structure available to date (Yoon
et al., 2010).
We have also been able to show that LPA is stably accom-
modated within the complete [RP105,MD-1]2 complex, and
in a manner that closely resembles that within TLR4 (Paramo
et al., 2013; Park et al., 2009), suggesting that the RP105
complex contains a true binding site for endotoxin and related
analogs. On the other hand, the overall architecture of thehts reserved
receptor and respective oligomerization interfaces were main-
tained irrespective of the ligand-bound state, suggesting that,
unlike [TLR4,MD-2]2 (Paramo et al., 2013; Park et al., 2009),
endotoxin binding is not required for RP105 dimerization. This
is consistent with the ability of the [RP105,MD-1]2 complex
to bind a range of ligands in vitro (Harada et al., 2010; Ohto
et al., 2011; Yoon et al., 2010, 2011). There is ongoing contro-
versy over the reported opposing physiological effects of
RP105 on TLR4 signaling, dependent upon the cell type. In
dendritic cells and macrophages the complex may down-
regulate LPS responses through a direct interaction with
TLR4,MD-2 (Divanovic et al., 2005, 2007; Ohto et al., 2011;
Yoon et al., 2011), whereas RP105 may stimulate B cells in a
MyD88-dependent fashion (Chaplin et al., 2011; Nagai et al.,
2012). Our results support the possibility that bound endotoxin
within RP105,MD-1 may help to occlude and, hence, compet-
itively inhibit the TLR4,MD-2 dimerization interface (Yoon et al.,
2011), facilitating its role as a ‘‘decoy receptor.’’ Moreover, its
capacity for binding endotoxin may enable RP105 to act as a
‘‘sink’’ that may sequester LPS from TLR4 under certain condi-
tions or act as a source under others. Irrespective of the (cell-
type dependent) mechanism of modulation of endotoxin host
sensitivity, our identification of biologically relevant binding
modes of both LPIVa and LPA now opens up potential path-
ways for the development of therapeutic molecules targeted to-
ward MD-1 and RP105.
EXPERIMENTAL PROCEDURES
Starting structures for bRP105,MD-1 and hRP105,MD-1 were based on their
corresponding X-ray structures (PDB: 3RG1 and 3B2D, respectively), while
iMD-1 systems were derived from the bovine complex (PDB: 3RG1, chain
H). Ligand orientations were based on a range of co-crystallized structures
of MD-1 and/or MD-2 (PDB: 3MU3, 2E59, 3FXI, 3RG1, 3B2D). An expanded
structure at 41 ns from the iMD-1LPIVa_hMD-2 system was structurally aligned
with the LPS-bound TLR4 X-ray structure (PDB: 3FXI) to introduce LPA into
the MD-1 cavity. The final 100-ns frame of the LPA system was used to
construct the myristate-bound MD-1 states, containing three (iMD-13myr),
four (iMD-14myr), five (iMD-15myr), or six (iMD-16myr) fully saturated myristic
acid molecules. For the apo systems, solvated ligand-free iMD-1 (iMD-1apo)
with 20 cavity-resident water molecules was constructed. During protein-
restrained equilibration, desolvation of the cavity was observed, prior to rapid
hydrophobic collapse during three 100-ns replicas. Similar results were
obtained in three additional replicas for which the positions of the internal
water molecules were enforced during equilibration. In an additional
‘‘expanded’’ system (iMD-1apo_exp), based on an initially LPA-bound cavity,
desolvation of the 30 cavity-resident waters and hydrophobic collapse was
again observed.
All systems were placed in a truncated octahedral box containing 0.1 M
NaCl solution, and equilibrated in the NPT ensemble with gradually reducing
position restraints on protein heavy atoms. Simulations were run using
GROMACS 4.5.5 (Hess et al., 2008), most with the CHARMM22/CMAP
(Bjelkmar et al., 2010; MacKerell et al., 1998) all-atom force field and
TIP3P water (Jorgensen et al., 1983) (Table 1). In umbrella sampling calcu-
lations, the glucosamine moiety of the lipid was pulled from the center of
mass of the protein in a direction normal to the cavity entrance, using a har-
monic potential with force constant of 1,000 kJ mol1 nm2. The weighted
histogram analysis method was used to calculate PMFs from the biased
distributions, with a relative tolerance of 106. 15–20 windows per system
were generated over a total 3 nm width, ensuring histogram overlap. Sta-
tistical errors were evaluated with the Bayesian bootstrap procedure, using
100 bootstrapped PMFs. Block analysis was used to ensure convergence of
the PMF profiles (Figures S7G and S7H), and beyond the initial 20% of
umbrella sampling, the total binding free energies remained within the limitsStructure 24, 20of error estimated from bootstrapping. 15 or 30 ns of sampling per window
was utilized for systems in the presence or absence of 0.1 M salt solution
with the latter 5 or 10 ns retained respectively for calculation of free-energy
curves and other z-dependent properties. All simulations were performed
using the leap-frog algorithm with a 2-fs time-step. The LINCS algorithm
(Hess et al., 1997) was used to constrain bond lengths. The van der Waals
interactions were smoothly switched off between 1 and 1.2 nm. Electro-
static interactions were calculated using the particle-mesh Ewald method
(Essmann et al., 1995), and the real-space sum was cut off at 1.2 nm.
The neighbor list was updated every ten steps using a cutoff of 1.4 nm.
The temperature was set to 298 K (velocity-rescale thermostat [Bussi
et al., 2007]) and the pressure to 1 bar (Parrinello-Rahman barostat with
isotropic coupling [Parrinello, 1981]) under periodic boundary conditions.
Further methodological details are given in Supplemental Experimental
Procedures.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and seven figures and can be found with this article online at http://dx.doi.
org/10.1016/j.str.2015.10.021.
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